When was Aperiomics founded?

Aperiomics was founded in 2013 and raised its 1st funding round 1 year after it was founded.

Where is Aperiomics located?

Aperiomics is headquartered in Ashburn, United States.

Who is the current CEO of Aperiomics?

Crystal Icenhour of Aperiomics.

Is Aperiomics a funded company?

Aperiomics is a funded company, having raised a total of $4.35M across 8 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Jul 01, 2014.

When was the latest funding round of Aperiomics?

Aperiomics' latest funding was a $***** Series A round on Dec 07, 2020, with participation from 5 investors. Its primary sector is Genomics. In United States, the Genomics sector has seen $1.97B in funding in 2026 to date.

Where does Aperiomics rank among its competitors?

Aperiomics ranks 207th amongst 625 active competitors, of which 148 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was HaystackAnalytics, which secured $5M in Sep, 2025.

Who are the top competitors of Aperiomics?

Aperiomics' top competitors include Nanopore Technologies, PacBio and Adaptive Biotechnologies. Among them, HaystackAnalytics secured the most recent funding round in September, 2025.

Aperiomics - 2026 Company Profile, Team, Funding & Competitors

Aperiomics is a deadpooled company based in Ashburn (United States), founded in 2013 by Keith Crandall. It operates as a Provider of pathogen detection through genomics and bioinformatics. Aperiomics has raised $4.35M in funding from investors like VentureSouth, The Launch Place and Pipeline Angels. The company has 625 active competitors, including 148 funded and 109 that have exited. Its top competitors include companies like Nanopore Technologies, PacBio and Adaptive Biotechnologies.

Company Details

Provider of pathogen detection through genomics and bioinformatics. The company uses a sequencing and genomic analysis approach, for pathogen discovery, diagnosing difficult cases of unknown etiology, pathogen surveillance, and monitoring of natural animal populations, as well as routine pathogen detection.

Website: aperiomics.com
Social

Key Metrics

Founded Year

2013

Location

Ashburn, United States

Stage

Deadpooled

Total Funding

$4.35M in 8 rounds

Latest Funding Round

Series A, Dec 07, 2020, $*****

Investors

VentureSouth & 10 more

Ranked

207^th among 625 active competitors

Similar Companies

Nanopore Technologies & 719 more

View Aperiomics' full profile

Aperiomics has raised a total funding of $4.35M over 8 rounds. Its first funding round was on Jul 01, 2014. Its latest funding round was a Series A round on Dec 07, 2020 for $*****. 5 investors participated in its latest round. Aperiomics has 11 institutional investors.

Here is the list of recent funding rounds of Aperiomics:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Dec 07, 2020	8704058	Series A	4500001	6814519	7547987	9203081
Nov 30, 2020	9535457	Conventional Debt	3323622	2379622	2389663	Tamiami Angel Funds
Oct 05, 2020	2140848	Series A	1808742	7397543	The Launch Place	4764442

Access funding benchmarks and valuations. Sign up today!

View details of Aperiomics's funding rounds and investors

The founders of Aperiomics is Keith Crandall.

Here are the details of Aperiomics' key team members:

Keith Crandall: Co-Founder & President of Aperiomics. They serve on the board of 1 company.
Crystal Icenhour: CEO of Aperiomics.

View details of Aperiomics's Founder profiles and Board Members

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Aperiomics include Nanopore Technologies, PacBio and Adaptive Biotechnologies. Here is the list of Top 10 competitors of Aperiomics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Nanopore Technologies 2005, Oxford (United Kingdom), Public	Manufacturer of portable and benchtop devices for real-time DNA sequencing	$1.34B	IP Group, GIC & 93 others	75/100
2nd	PacBio 2004, Menlo Park (United States), Public	Developer of instrument systems and software for real-time sequencing of single-molecules	$410M	Deerfield, Kleiner Perkins & 24 others	72/100
3rd	Adaptive Biotechnologies 2009, Seattle (United States), Public	Provider of clinical diagnostics, and drug discovery for immune diseases	$419M	Viking Global Investors, Matrix & 21 others	72/100
4th	Foundation Medicine 2010, Cambridge (United States), Acquired	Provider of genomics-based diagnostics test for cancer	$96.5M	Redmile Group, Deerfield & 11 others	70/100
5th	MeMed 2009, Tirat Carmel (Israel), Series D	Provider of machine learning based diagnostic solutions for infectious diseases	$163M	La Maison Partners, Ping An & 23 others	69/100
6th	HaystackAnalytics 2018, Mumbai (India), Seed	Provider of genomics technology for personalized clinical decisions	$17.3M	STRIVE, Sun Pharma & 33 others	67/100
7th	Complete Genomics 2006, San Jose (United States), Acquired	Developer of DNA sequencing platform for human genome sequencing and analysis	$125M	Enterprise Partners Venture Capital, Orbimed ... & 8 others	66/100
8th	Ultima Genomics 2016, Newark (United States), Series D	Developer of high-throughput NGS instrument for research	$600M	General Atlantic, Lightspeed Venture Partners ... & 8 others	62/100
9th	Lantern Pharma 2013, Dallas (United States), Public	Developing drug and companion diagnostics for multi-drug resistant cancers	$7.12M	Green Park & Golf Ventures, Bios Partners ... & 3 others	62/100
10th	Personalis 2011, Menlo Park (United States), Acquired	Provider of genomic sequencing and diagnosis software for the healthcare industry	$87.3M	Abingworth, Lightspeed Venture Partners & 5 others	61/100
207th	Aperiomics 2013, Ashburn (United States), Deadpooled	Provider of pathogen detection through genomics and bioinformatics	$4.35M	Atlanta Technology Angels, Springboard Enterprises ... & 9 others	32/100